The decision by Johnson & Johnson (J&J) to use a priority review voucher for the submission of the biologics license application for guselkumab apparently paid off. The drug, branded Tremfya, gained FDA approval late Thursday, four months prior to its estimated PDUFA date of Nov. 17.